- Home
- NTHI vs PROF Comparison
NTHI vs PROF Comparison
Compare NTHI & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTHI | PROF |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 195.5M | 230.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NTHI | PROF |
|---|---|---|
| Price | $8.20 | $7.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 66.3K | ★ 288.0K |
| Earning Date | 02-19-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $59,990.00 | ★ $14,297,000.00 |
| Revenue This Year | N/A | $64.23 |
| Revenue Next Year | N/A | $113.06 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.94 |
| 52 Week Low | $3.20 | $3.76 |
| 52 Week High | $25.00 | $8.95 |
Technical Indicators
Market Signals| Indicator | NTHI | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 52.49 |
| Support Level | $8.11 | $7.45 |
| Resistance Level | $10.19 | $8.60 |
| Average True Range (ATR) | 0.86 | 0.59 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 12.92 | 41.60 |
Price Performance
Historical ComparisonAbout NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.